is aiming to develop a safe new treatment that prevents excessive bleeding in fetuses and newborns caused by FNAIT. Today, such bleedings may cause life-long disabilities or death.
Some excessive bleedings in foetuses and neonates occur because there are too few platelets to stop the bleeding. This may be caused by Foetal Neonatal Alloimmune Thrombocytopenia (FNAIT).
is an EU-funded collaboration between Prophylix Pharma, Larix A/S and leading hospitals, blood banks and universities in Europe aimed at developing a prophylaxis against FNAIT.